ArticleCNS neuroscience & therapeutics2025
Osteocalcin Ameliorates CUMS-Induced Depressive-Like Behaviors by Reducing Mitochondrial Damage in Hippocampal Neurons.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mitochondrial-inflammation crosstalk in major depressive disorder: molecular mechanisms and therapeutic implications.Molecular psychiatry · 2026Pooled it
- The role of ucOCN in aerobic exercise induced amelioration of autism spectrum disorder phenotypes.iScience · 2026Article
- Analysis of gut microbiota and intestinal mucosal neurotransmitter changes and their correlation in adolescent depression mice.Annals of general psychiatry · 2026Article
- Drp1-Dependent Mitochondrial Fission in the Hippocampus Drives Chronic Stress-Induced Depressive-like Behaviors in Mice.International journal of molecular sciences · 2026Article
- Molecules of mood: the integrated molecular transducers of exercise's antidepressant effects.Molecular genetics and genomics : MGG · 2026Review
- Osteoimmuno-brain axis: a bridge connecting osteoporosis and cognitive decline and its clinical significance in dementia and Alzheimer's disease.Frontiers in immunology · 2026Review
- Osteocalcin Ameliorates CUMS-Induced Depressive-Like Behaviors by Reducing Mitochondrial Damage in Hippocampal Neurons.CNS neuroscience & therapeutics · 2025Article
- Association of baseline osteocalcin and femoral neck bone mineral density in healthy women with future risk of fractures, cardiovascular disease, diabetes and death.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDepression is a common psychological disorder characterized by limited treatments. Osteocalcin (OCN), a bioactive protein that originates from bone tissue, has been implicated in emotional regulation and the reduction of oxidative stress in peripheral tissues. However, the precise mechanisms by which OCN functions within the central nervous system are still not fully understood.
aimsThis study aimed to clarify the function of OCN in depression-like behavior, identify its functional brain region, and explore its impact on neuronal mitochondrial function and the exact molecular mechanisms involved. MATERIALS AND
methodsIn this study, the antidepressant effects and mitochondrial protective properties of OCN were examined in adult male C57BL/6 mice subjected to chronic unpredictable mild stress (CUMS); then, the potential molecular pathway was explored both in vivo and in vitro conditions. The CUMS model was employed to induce depression in mice. Initially, depressive-like behaviors in CUMS mice were evaluated following a 3-week intraperitoneal injection of OCN. Subsequently, the expression levels and distribution of GPR158 and GPR37 were examined. Next, the specific effects of OCN on mitochondrial function were determined. Finally, the molecular pathways through which OCN demonstrates its antidepressant properties and offers mitochondrial protection were explored in both in vivo and in vitro conditions.
resultsOCN significantly alleviated depressive-like symptoms in CUMS mice, which was evidenced by improvements in weight variations, increased consumption of sucrose, and a greater total distance traveled in the open field test (OFT). Additionally, it shortened the immobility time observed in both the forced swim test and the tail suspension test. OCN influenced hippocampal neuronal activity by modifying the expression levels of PR158 and GPR37, demonstrated by its ability to counteract the downregulation of both receptors in experiments conducted in vivo and in vitro. Furthermore, OCN mitigated mitochondrial damage in neurons induced by depression through the PKA/AMPK/PGC1α signaling pathway, resulting in elevated ATP levels and reduced ROS levels. Notably, inhibiting PKA and AMPK abolished OCN's effects on PGC-1α, ATP production, and ROS reduction. DISCUSSION: The administration of OCN significantly ameliorates depressive-like behaviors in mice, demonstrating the crucial involvement of the bone-brain pathway in depression pathogenesis and offering further evidence for a better understanding of how peripheral bone tissue affects brain function. The results also provide a novel perspective on the function of OCN in neurons, paving the way for further exploration of innovative therapeutic approaches for central nervous system disorders associated with mitochondrial dysfunction.
conclusionOur results indicate that OCN mitigated oxidative stress damage and enhanced mitochondrial function through the AMPK/PGC-1α pathway, demonstrating antidepressant properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.